		Item No	Recommendation
Title and abstract	/	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
L			(b) Provide in the abstract an informative and balanced summary of what was done
			and what was found
Introduction			
Background/rationale		2	Explain the scientific background and rationale for the investigation being reported
Objectives	\mathcal{J}	3	State specific objectives, including any prespecified hypotheses
Methods			
Study design		4	Present key elements of study design early in the paper
Setting		. 5	Describe the setting, locations, and relevant dates, including periods of recruitment,
Setting	✓	, ,	exposure, follow-up, and data collection
Participants		6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of
			selection of participants. Describe methods of follow-up
			Case-control study—Give the eligibility criteria, and the sources and methods of
			case ascertainment and control selection. Give the rationale for the choice of cases
			and controls
			/Cross-sectional study—Give the eligibility criteria, and the sources and methods of
		V	selection of participants
			(b) Cohort study—For matched studies, give matching criteria and number of
			exposed and unexposed
			Case-control study—For matched studies, give matching criteria and the number of
			controls per case
Variables	/	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect
			modifiers. Give diagnostic criteria, if applicable
Data sources/		8*	For each variable of interest, give sources of data and details of methods of
measurement	/		assessment (measurement). Describe comparability of assessment methods if there
			is more than one group
Bias		9	Describe any efforts to address potential sources of bias
Study size		10	Explain how the study size was arrived at
Quantitative variables		11	Explain how quantitative variables were handled in the analyses. If applicable,
			describe which groupings were chosen and why
Statistical methods	/	12	(a) Describe all statistical methods, including those used to control for confounding
	/		(b) Describe any methods used to examine subgroups and interactions
			(c) Explain how missing data were addressed
			(d) Cohort study—If applicable, explain how loss to follow-up was addressed
			Case-control study—If applicable, explain how matching of cases and controls was
			addressed
			Cross-sectional study—If applicable, describe analytical methods taking account of
			sampling strategy
			(e) Describe any sensitivity analyses
Continued on next page			(<u> </u>

Participants 13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible,		
	(a) report numbers of individuals at each stage of study—eg numbers potentially eligible,		
	examined for eligibility, confirmed eligible, included in the study, completing follow-up, and		
_	analysed		
_	(b) Give reasons for non-participation at each stage		
	(c) Consider use of a flow diagram		
Descriptive 14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information		
data	on exposures and potential confounders		
_	(b) Indicate number of participants with missing data for each variable of interest		
	(c) Cohort study—Summarise follow-up time (eg, average and total amount)		
Outcome data 15*	Cohort study—Report numbers of outcome events or summary measures over time		
_	Case-control study—Report numbers in each exposure category, or summary measures of		
, _	exposure		
_	Cross-sectional study—Report numbers of outcome events or summary measures		
Main results 16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their		
v	precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and		
_	why they were included		
	(b) Report category boundaries when continuous variables were categorized		
	(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful		
	time period		
Other analyses 17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity		
	analyses		
Discussion			
Key results 18	Summarise key results with reference to study objectives		
Limitations 19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.		
	Discuss both direction and magnitude of any potential bias		
Interpretation 20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity		
	of analyses, results from similar studies, and other relevant evidence		
Generalisability 21	Discuss the generalisability (external validity) of the study results		
Other information			
Funding 22	Give the source of funding and the role of the funders for the present study and, if applicable,		
	for the original study on which the present article is based		

^{*}Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: http://dx.doi.org/10.21037/AJO-19-53

^{*}As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version.